Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

22.58 -0.47 (-2.04%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Where Apellis Pharmaceuticals Stands With Analysts ↗

August 09, 2022

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:

Via Benzinga

7 Cheap Biotech Stocks to Buy Now ↗

August 03, 2022

These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.

Via InvestorPlace

Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

July 27, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Recap of Tuesday's Biotech Catalysts - End Of The Day Summary ↗

July 19, 2022

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness...

Via Benzinga

HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals ↗

July 19, 2022

Via Benzinga

Expert Ratings for Apellis Pharmaceuticals ↗

May 05, 2022

Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter:

Via Benzinga

July 20, 2022

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and...

Via Benzinga

Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher ↗

July 19, 2022

U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 19, 2022

Via Benzinga

Dow Climbs Over 500 Points as Upbeat Earnings Roll In ↗

July 19, 2022

The Dow Jones Industrial Average is up 510 points midday, as the newest string of earnings reports shows companies working through the current economic pressures.

Via Talk Markets

Dow Surges 500 Points; Johnson & Johnson Lowers Guidance ↗

July 19, 2022

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday.

Via Benzinga

This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session ↗

July 19, 2022

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue...

Via Benzinga

Why U.S. Stocks Are Trading Higher; Housing Starts Drop Further In June ↗

July 19, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 350 points on Tuesday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022 ↗

July 19, 2022

Upgrades

Via Benzinga

Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment ↗

July 19, 2022

The drug could be the first ever FDA-approved treatment for geographic atrophy.

Via Investor's Business Daily

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗

July 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Apellis Pharmaceuticals Stock Is Soaring ↗

July 19, 2022

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher Tuesday after the company announced the U.S. Food and Drug Administration accepted and granted priority review designation for the...

Via Benzinga

Apellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority Review ↗

July 19, 2022

The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation for Apellis Pharmaceuticals’ (NASDAQ: APLS) New Drug Application (NDA) for the intravitreal...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 19, 2022

Via Benzinga

Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗

July 13, 2022

ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level.

Via Investor's Business Daily

Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

July 08, 2022

Apellis Pharmaceuticals stock saw its Relative Strength (RS) Rating upgraded to 85 Friday, up from 79 a day earlier.

Via Investor's Business Daily

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗

June 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data ↗

June 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Apellis Begins Paitent Dosing In Late-Stage Study Of Rare Kidney Disease Candidate ↗

June 07, 2022

Apellis Pharmaceuticals (NASDAQ: APLS) has dosed first patient in the VALIANT Phase 3 clinical study of its drug candidate Pegcetacoplan for primary immune-complex membranoproliferative...

Via Benzinga

Expert Ratings for Apellis Pharmaceuticals ↗

May 24, 2022

Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Goldman Sachs Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know ↗

May 24, 2022

Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and lower its price target from $94.00 to $84.00. Shares of Apellis Pharmaceuticals are trading down 2.3%...

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Apellis Pharmaceuticals's Earnings: A Preview ↗

May 03, 2022

Apellis Pharmaceuticals (NASDAQ:APLS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Expert Ratings for Apellis Pharmaceuticals ↗

April 14, 2022

Over the past 3 months, 4 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022 ↗

April 14, 2022

Upgrades

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.